Introduction Introduction
This quality standard covers the prevention, assessment, diagnosis and management of skin cancer (malignant melanoma and non-melanoma) in children, young people and adults. For more information see the skin cancer topic overview.
NICE quality standards focus on aspects of health and social care that are commissioned locally.
Areas of national policy, such as changes to national commissioning arrangements and legislation, are therefore not covered by this quality standard.
Why this quality standard is needed
There are 2 main groups of skin cancer: malignant melanoma, which can prove fatal, and nonmelanoma skin cancers (main types: squamous cell carcinoma and basal cell carcinoma), which are rarely fatal. Over the past decade the incidence of malignant melanoma in the UK has increased by almost 50%. There were about 14,500 new cases of malignant melanoma in the UK in 2013.
Non-melanoma skin cancers are much more common than malignant melanomas, but because of current registration practices their true number is significantly underestimated.
The quality standard is expected to contribute to improvements in the following: skin cancer prevention skin cancer awareness early diagnosis of skin cancer skin cancer referrals appropriate excisions of skin cancer skin cancer survival patient experience.
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How this quality standard supports delivery of outcome frameworks NICE quality standards are a concise set of prioritised statements designed to drive measurable improvements in the 3 dimensions of quality -patient safety, patient experience and clinical effectiveness -for a particular area of health or care. They are derived from high-quality guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following 2 outcomes frameworks published by the Department of Health: Tables 1 and 2 show the outcomes, overarching indicators and improvement areas from the frameworks that the quality standard could contribute to achieving.
T 
Safety and people's experience of care
Ensuring that care is safe and that people have a positive experience of care is vital in a high-quality service. It is important to consider these factors when planning and delivering services relevant to skin cancer. NICE has developed guidance and an associated quality standard on patient experience in adult NHS services (see the NICE pathway on patient experience in adult NHS services), which should be considered alongside this quality standard. They specify that people receiving care should be treated with dignity, have opportunities to discuss their preferences, and be supported to understand their options and make fully informed decisions. They also cover the provision of information to people using services. Quality statements on these aspects of patient experience are not usually included in topic-specific quality standards. However, recommendations in the development sources for quality standards that affect people's experience of using services and are specific to the topic are considered during quality statement development.
Coordinated services
The quality standard for skin cancer specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole skin cancer care pathway. A person-centred, integrated approach to providing services is fundamental to delivering highquality care to people with skin cancer.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality skin cancer service are listed in related NICE quality standards.
T Tr raining and competencies aining and competencies
The quality standard should be read in the context of national and local guidelines on training and competencies. All healthcare professionals involved in assessing, caring for and treating people with skin cancer should have sufficient and appropriate training and competencies to deliver the actions and interventions described in the quality standard. Quality statements on staff training and competency are not usually included in quality standards. However, recommendations in the development sources on specific types of training for the topic that exceed standard professional training are considered during quality statement development. 
Quality statement
Local authority health promotion activities on preventing skin cancer and recognising early signs are consistent with the messages in any national campaigns.
Rationale
Skin cancer is the most common form of cancer and, even though most types are preventable, its incidence has been increasing. People can recognise changes to their skin in early stages of the disease but some are still seeking help too late. Local health promotion activities, with messages consistent with any national campaigns, should minimise public confusion and increase the likelihood of behaviour change.
Quality measures
Structure Structure
Evidence that the local authority health promotion activities on preventing skin cancer and recognising early signs are consistent with the messages in any national campaigns. 
Data sour

What the quality statement means for public health practitioners and commissioners
Public health pr Public health practitioners actitioners ensure that they implement local authority health promotion activities on preventing skin cancer and recognising early signs using messages consistent with those in any national campaigns.
Commissioners Commissioners (local authorities) ensure that local authority health promotion activities on preventing skin cancer and recognising early signs are consistent with the messages in any national campaigns.
What the quality statement means for people in the community P People in the community eople in the community are given advice about how to prevent skin cancer, and how to recognise early signs, through local authority health promotion activities that reinforce the messages in any national skin cancer campaigns.
Source guidance
Sunlight exposure: risks and benefits (2016) NICE guideline NG34, recommendations 1.1.3 and 1.1.13
Skin cancer (QS130) Quality statement 2: GPs managing low-risk basal cell carcinoma Quality statement 2: GPs managing low-risk basal cell carcinoma
Quality statement
GPs who manage low-risk basal cell carcinoma, including GPs with a special interest (GPwSI), maintain and audit records of their caseload.
Rationale
Low-risk basal cell carcinoma can sometimes be managed by GPs in the community, which can be more convenient for patients. Treatment in the community can also frequently be provided at a lower cost and free up capacity in hospitals. However, it is essential that this is balanced with ensuring that care offered in the community is as safe and effective as that in hospital. Maintaining and auditing records of their caseload can help in demonstrating competence.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that GPs who manage low-risk basal cell carcinoma, including GPwSI, maintain and audit records of their caseload. 
Data sour
What the quality statement means for patients and carers
P People who are ha eople who are having treatment from a GP for a type of skin cancer called low-risk basal cell ving treatment from a GP for a type of skin cancer called low-risk basal cell carcinoma carcinoma receive treatment that is safe and effective.
Source guidance
Improving outcomes for people with skin tumours including melanoma (2010) NICE cancer service guidance 8, 'Models of care'.
Definitions of terms used in this quality statement
L Low-risk basal cell carcinoma ow-risk basal cell carcinoma
Low-risk basal cell carcinoma is defined as set out in 'Models of care' in NICE's guidance on improving outcomes for people with skin tumours including melanoma.
Competence in managing low-risk basal cell carcinoma Competence in managing low-risk basal cell carcinoma NICE's guidance on improving outcomes for people with skin tumours including melanoma outlines criteria for assessing competence and accrediting practitioners.
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Quality statement 3: Suspected cancer path Quality statement 3: Suspected cancer pathwa way referr y referrals als
Quality statement
People with suspected malignant melanoma are referred using a suspected cancer pathway for an appointment within 2 weeks.
Rationale
Timely referral to a specialist is important for a quick and accurate diagnosis of skin cancer. The specialist will usually be working as part of the local hospital skin cancer multidisciplinary team and can provide rapid diagnosis, treatment, management and follow-up for most people with skin cancer. Some squamous cell carcinomas, basal cell carcinomas and less common skin cancers may also need urgent referrals, in line with clinical judgement.
Quality measures
Structure Structure
Evidence of local arrangements and clinical protocols ensuring that a suspected cancer pathway is in place for suspected malignant melanoma.
Data sour
Data source: ce: Local data collection.
Process Process
Proportion of confirmed malignant melanomas that were referred using a suspected cancer pathway for an appointment within 2 weeks.
Numerator -number in the denominator that were referred using a suspected cancer pathway for an appointment within 2 weeks.
Denominator -number of confirmed malignant melanomas.
Data sour Data source: ce: NHS England Cancer waiting times.
Outcome Outcome a) Time between GP referral for suspected skin cancer and specialist assessment. 
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders (GP practices and secondary care providers) ensure that systems are in place for people presenting with suspected malignant melanoma to be referred using a suspected cancer pathway for an appointment within 2 weeks.
Healthcare professionals
Healthcare professionals (such as GPs or secondary care clinicians) ensure that they refer people with suspected malignant melanoma using a suspected cancer pathway for an appointment within 2 weeks.
Commissioners Commissioners (NHS England, clinical commissioning groups) ensure that services they commission refer people with suspected malignant melanoma using a suspected cancer pathway for an appointment within 2 weeks.
What the quality statement means for patients and carers
P People eoplewho ha who hav ve skin lesions, such as damaged or injured patches of skin or new e skin lesions, such as damaged or injured patches of skin or new, large, changing or , large, changing or unusual looking moles unusual looking moles, and whose GP thinks it is a type of skin cancer called malignant melanoma, are referred for an appointment to see a specialist within 2 weeks.
Source guidance
Suspected cancer: recognition and referral (2015) NICE guideline NG12, recommendations 1.7.1 and 1.7.2
Definitions of terms used in this quality statement
Suspected cancer path Suspected cancer pathwa way referr y referral al
The patient is seen within the national target for cancer referrals. This was 2 weeks at the time of publication of the NICE guideline on suspected cancer: recognition and referral.
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Quality statement 4: Dermoscop Quality statement 4: Dermoscopy y
Quality statement
People with pigmented skin lesions undergoing a specialist assessment have the lesions examined using dermoscopy.
Rationale
Dermoscopy performed by suitably trained specialists is more sensitive and more specific in classifying skin lesions than clinical examination with the naked eye. It lessens the chance of missing a diagnosis of melanoma and reduces the number of unnecessary surgical procedures to remove benign lesions.
Quality measures
Evidence of local arrangements and clinical protocols to ensure that people undergoing specialist assessment of pigmented skin lesions are examined using dermoscopy.
Data sour
Process Process
Proportion of pigmented skin lesions undergoing specialist assessment that are examined using dermoscopy.
Numerator -number in the denominator examined using dermoscopy.
Denominator -number of pigmented skin lesions undergoing specialist assessment. 
Data sour
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders (local hospital skin cancer multidisciplinary teams and specialist skin cancer multidisciplinary teams) ensure that systems are in place for using dermoscopy during specialist assessment of pigmented skin lesions. Service providers should also ensure that those using dermoscopy have formal training.
Healthcare professionals Healthcare professionals (members of local hospital skin cancer multidisciplinary teams or specialist skin cancer multidisciplinary teams) undertaking specialist assessment of pigmented skin lesions ensure that they examine the lesions using dermoscopy. They should include formal training as part of their continuing professional development.
Commissioners Commissioners (clinical commissioning groups and NHS England) ensure that the specialist services they commission have trained specialists who use dermoscopy to examine pigmented skin lesions.
What the quality statement means for patients and carers
P People with skin lesions (such as damaged or injured patches of skin or new eople with skin lesions (such as damaged or injured patches of skin or new, large, changing or , large, changing or unusual looking moles) that are being assessed b unusual looking moles) that are being assessed by a specialist y a specialist have the lesions examined using a magnifying tool called a dermatoscope, which gives a more accurate view of the lesion.
Source guidance
Melanoma: assessment and management (2015) NICE guideline NG14, recommendation 1.2.1
Definitions of terms used in this quality statement
Specialist assessment Specialist assessment
An assessment carried out by a doctor trained in the diagnosis of skin malignancy, normally a dermatologist, who is a member of either a local hospital skin cancer multidisciplinary team or a specialist skin cancer multidisciplinary team. 
What the quality statement means for patients and carers
P People with a type of skin cancer called eople with a type of skin cancer calledmalignant melanoma or squamous cell carcinoma malignant melanoma or squamous cell carcinoma have a skin cancer nurse specialist who can provide information, advice and support.
Source guidance
Melanoma: assessment and management (2015) NICE guideline NG14, recommendation 1.1.1 Improving outcomes for people with skin tumours including melanoma (2006) NICE cancer service guidance, 'Organisation of skin cancer services'.
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Quality statement 6: Sentinel lymph node biopsy Quality statement 6: Sentinel lymph node biopsy
Quality statement
People with stage IB-IIC melanoma with a Breslow thickness of more than 1 mm have a discussion about the advantages and disadvantages of sentinel lymph node biopsy as a staging procedure.
Rationale
Sentinel lymph node biopsy helps to find out whether cancer has spread to the lymph nodes. It is better than ultrasound scans at finding very small deposits of cancers in the lymph nodes. However, it is not a form of treatment and, as with all invasive procedures, it has associated risks and complications that should be discussed with the person to enable shared decision making.
Quality measures
Evidence of local arrangements and clinical protocols to ensure that the advantages and disadvantages of sentinel lymph node biopsy as a staging procedure are discussed with people with stage IB-IIC melanoma with a Breslow thickness of more than 1 mm.
Data sour
Process Process
Proportion of people with stage IB-IIC melanoma with a Breslow thickness of more than 1 mm who have a discussion about the advantages and disadvantages of sentinel lymph node biopsy as a staging procedure.
Numerator -number in the denominator who have a discussion about the advantages and disadvantages of sentinel lymph node biopsy as a staging procedure.
Denominator -number of people with stage IB-IIC melanoma with a Breslow thickness of more than 1 mm.
Data sour
Data source: ce: Local data collection. professional. In this procedure, 1 or 2 lymph nodes near the cancer are removed and checked to see whether there is melanoma in them. Sentinel lymph node biopsy does not cure melanoma, but it can help to find out whether it has spread and may lead to other treatment options.
Source guidance
Melanoma: assessment and management (2015) NICE guideline NG14, recommendation 1.5.2
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Quality statement
People with unresectable or metastatic melanoma are offered genetic testing of the tumour.
Rationale
Genetic testing of tumour tissue can help with choosing more targeted and effective treatment for people with unresectable or metastatic melanoma.
Quality measures
Evidence of local arrangements and clinical protocols to provide genetic testing of the tumours for people with unresectable or metastatic melanoma.
Data sour
Process Process
Proportion of people with unresectable or metastatic melanoma who receive genetic testing of the tumour.
Numerator -number in the denominator who receive genetic testing of the tumour.
Denominator -number of people with unresectable or metastatic melanoma. 
Data sour
Source guidance
Melanoma: assessment and management (2015) NICE guideline NG14, recommendation 1.2.7
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Using the quality standard Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.
We have indicated if current national indicators exist that could be used to measure the quality statements. If there is no national indicator that could be used to measure a quality statement, the quality measure should form the basis for audit criteria developed and used locally.
See NICE's what makes up a NICE quality standard? for further information, including advice on using quality measures.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.
NICE's quality standard service improvement template helps providers to make an initial assessment of their service compared with a selection of quality statements. It includes assessing current practice, recording an action plan and monitoring quality improvement. This tool is updated monthly to include new quality standards.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered alongside the documents listed in development sources, NICE's cancer service guidance on improving outcomes for people with skin cancer including melanoma and the National Cancer Peer Review Progamme's Manual for cancer services: skin measures.
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Div Diversity ersity, equality and language , equality and language During the development of this quality standard, equality issues have been considered and equality assessments are available.
Good communication between health, public health and social care professionals and people with skin cancer is essential. Treatment, care and support, and the information given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English. People with skin cancer should have access to an interpreter or advocate if needed.
Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties.
De Dev velopment sources elopment sources
Further explanation of the methodology used can be found in the quality standards process guide.
Evidence sources
The documents below contain recommendations from NICE guidance that were used by the quality standards advisory committee to develop the quality standard statements and measures. 
